Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
Model scores of the 29,894 trials active now.
Model score 17% for any early termination, 13% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 17% of the time (276 trials).
Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.
How it ended
Completed on 2013-03-31, after 2008-04-30 start.
The score above never used this outcome: finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.
Termination over time, as the model saw it at the start
Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-03-31. The rest of the way to 100% is still running.
From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.
What moved the score
-
Wording of the registration (title, summary, criteria) (raises risk) · Wording
Phrases that raised it: concurrentchemotherapycancersince priorpain
Phrases that lowered it: trialcontainclinicalphase iiidrugs -
Sponsor's past termination rate: 2.9% (lowers risk) · Sponsor's track record
-
Design: crossover (lowers risk) · Design
-
Accepts healthy volunteers: No (raises risk) · Who can join
-
Minimum age: 25 (lowers risk) · Who can join
-
Drug's FAERS reports marked serious: 47.8% (lowers risk) · Drug's FDA history
-
Phase: 3 (lowers risk) · Design
-
Trials the sponsor started in the prior 2 years: 32 (lowers risk) · Sponsor's track record
-
Has a data monitoring committee: Yes (raises risk) · Design
-
Sponsor type: academic or other (raises risk) · Sponsor's track record
-
Disease area, cancer: No (lowers risk) · Disease area
-
Maximum age: not given (raises risk) · Who can join
-
Primary purpose: supportive care (raises risk) · Design
-
Drug's FAERS reports with a death: 4.2% (lowers risk) · Drug's FDA history
-
Disease area, neurology: Yes (raises risk) · Disease area
-
Drug's FAERS reports before start: 11132 (raises risk) · Drug's FDA history
-
Number of arms: 2 (raises risk) · Design
Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.
The trial
Design
- Phase
- 3 (typical: 2)
- Number of arms
- 2
- Allocation
- randomized
- Design
- crossover (typical: parallel)
- Primary purpose
- supportive care (typical: treatment)
- Blinding
- double (typical: none)
- Has a data monitoring committee
- Yes (typical: 56% yes)
- Responsible party
- sponsor
- Collaborators
- 1 (typical: 0)
- Keywords listed
- 4 (typical: 1)
Who can join
- Minimum age
- 25 (typical: 18)
- Maximum age
- not given (typical: 71)
- Sex
- all
- Accepts healthy volunteers
- No (typical: 9% yes)
Sponsor's track record
- Sponsor type
- academic or other
- Sponsor's past trials
- 105 (typical: 32)
- Sponsor's past termination rate
- 2.9% (typical: 9.9%)
- Trials the sponsor started in the prior 2 years
- 32 (typical: 19)
Drug's FDA history
- Drugs with FDA adverse-event history
- 1
- Drug has FAERS history
- Yes (typical: 64% yes)
- Drug's FAERS reports before start
- 11132 (typical: 2148)
- Drug's FAERS reports in the prior 12 months
- 3080 (typical: 412.5)
- Drug's FAERS reports marked serious
- 47.8% (typical: 85.6%)
- Drug's FAERS reports with a death
- 4.2% (typical: 15.9%)
Disease area and drugs
- Disease areas
- neurology
- Drugs matched to FDA substances
- duloxetine
Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.
Similar finished trials
- Dextromethorphan in Chemotherapy-induced Peripheral Neuropathy Management NCT02271893 · started 2014 · scored riskier than 49% of active trials terminated
- Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer NCT00516503 · started 2008 · scored riskier than 88% of active trials completed
- Clinical Study on Acetyl-L-Carnitine NCT01526564 · started 2008 · scored riskier than 25% of active trials completed
- Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy NCT05388058 · started 2022 · scored riskier than 78% of active trials completed
- Study of Nicotine for Pain Associated With Chemotherapy-Induced Peripheral Neuropathy NCT04468230 · started 2020 · scored riskier than 84% of active trials terminated
Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.